AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 251 min read$CLX

Clorox CEO Linda Rendle receives 50,988 stock units

Clorox CEO Linda Rendle received 50,988 restricted stock units, vesting in four equal installments from 2027 to 2030. The shares were granted at $83.94 each, with Rendle's direct holdings increasing to 252,149 shares. The vesting schedule is tied to specific dates in October each year.

Original reporting
stocktitan.net
Published Sep 25, 2026, 9:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CLX
Neutral
high confidence
Mentioned
$CLX
Relevance
6/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLXNeutralLow
01

Why it matters

The award is a routine compensation event with modest dilution; unlikely to move the stock materially.

02

Market read

Primary insider filing; low trading relevance.

03

What to watch

Future performance and retention risk tied to vesting schedule.

Relevance 6/10Novelty 6/10Timing: post‑transaction Sep 23 2026

Background

Form 4 filing discloses insider equity compensation for CLX's CEO.

Company-level read

Ticker impact

$CLXNeutralHigh confidence
Context

CEO Linda Rendle was granted 50,988 restricted stock units at $83.94 per share, vesting over four years.

Expected impact

Minimal short‑term price effect; potential slight upside if vesting aligns with strong performance.

Evidence & confidence

Insider equity awards are routine; the size relative to market cap is small, so market reaction is likely limited.

Market effects

Sector

None significant for the consumer products sector.

Regional

No regional impact.

Global

Limited to CLX shareholders.

Counterpoint

What could challenge this read

The grant could signal confidence from management, suggesting potential upside.

Key entities

  • person
    Linda J. Rendle

    Chief Executive Officer of Clorox Co.

  • company
    Clorox Co.

    Consumer products company (ticker CLX).

Read at source← All news

Related articles

SEP 17
$CLXMedAI 8/10

Clorox stock hits 52-week low at 84.69 USD

Clorox (CLX) stock hit a 52-week low of $84.74, down 31.51% over the past year. Despite this, InvestingPro suggests it's undervalued with a 5.89% dividend yield. Q4 earnings per share were $1.66, missing estimates. UBS raised its price target to $105, maintaining a Neutral rating. Goldman Sachs and Morgan Stanley reported on broader consumer staples trends.

investing.com2 min
SEP 3
$CLXMed

Can Cost Savings Offset Inflation & Protect Clorox's Margins?

Clorox (CLX) reported a 520 basis point gross margin contraction in Q4 fiscal 2026 due to inflation and mix challenges. The company is focusing on cost savings and productivity initiatives to offset inflationary pressures, but expects margins to remain pressured in fiscal 2027. CLX shares have risen 5.2% in the past three months, with a forward P/E of 15.97X.

finance.yahoo.com2 min
AUG 21
$CLXMedAI 8/10

How GOJO Could Shape Clorox's Fiscal 2027 Growth and Margin Outlook

Clorox (CLX) expects fiscal 2027 net sales to rise 13-14%, with GOJO contributing 9.5 points. Q1 sales projected at 31-32%, including 15 points from GOJO. Adjusted earnings forecasted at $5.70-$6.00 per share, up 3-8%. Gross margin expected at 42%, with pressure from GOJO inventory costs and inflation. Integration costs and inflation pose near-term challenges.

tradingview.com3 min
AUG 21
$CLXMedAI 8/10

Is Clorox Stock Worth Buying as GOJO Growth Meets Margin Pressure?

Clorox (CLX) reports Q4 net sales of $1.95B, up 2% YoY, with GOJO contributing 10 percentage points. Fiscal 2027 sales expected to rise 13-14%, with adjusted EPS at $5.70-$6.00. Gross margins declined due to inflation and higher costs. Organic sales growth is muted, with ERP comparisons aiding growth. CLX trades at 17.9X forward earnings, below its sub-industry multiple.

tradingview.com3 min
AUG 14
$CLXMed

Are Wall Street Analysts Predicting Clorox Stock Will Climb or Sink?

The article says The Clorox Company (CLX) shares have lagged the S&P 500 over 52 weeks, down 13.7% versus SPX up 20.6%. After Q4 2026 results on Aug. 3, CLX rose 6.5% on $1.95B sales and adjusted EPS $1.66, plus FY2027 net sales growth guidance of 13%-14%. Analysts: consensus Hold, JPMorgan raised PT to $95; stock trades above the mean $96.94, with a Street-high $117.

yahoo.com6 min
AUG 11
$CLXMedAI 8/10

Clorox (CLX) Q4 2026 Earnings Call Transcript

Clorox (CLX) reported Q4 FY2026 net sales of $1.95B, down 2% (GOJO added about 10 points). Organic sales fell 13% and adjusted EPS was $1.66, down 42%. Gross margin was 41.3%. For FY2027, it guided organic sales growth of 3.5% to 4.5% and adjusted EPS of $5.70 to $6.00, citing inflation headwinds of $200M+.

fool.com6 min